Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells

Journal of Urology

Volumn 170, Issue 1, 2003, Pages 246-252

  Oades, Grenville M ^a,c   Senaratne, Siddhika G ^b   Clarke, Ian A ^b   Kirby, Roger S ^a   Colston, Kay W ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Mevalonic acid; Neoplasm metastasis; Prostate; Prostatic neoplasms

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; CASPASE INHIBITOR; FARNESOL; MEVALONIC ACID; NITROGEN; PAMIDRONIC ACID; PROTEIN BAX; PROTEIN BCL 2; RAS PROTEIN; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; ASSAY; BONE METASTASIS; CANCER STAGING; CELL CYCLE; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; DNA STRAND BREAKAGE; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PRENYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 0037664952     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000070685.34760.5f     Document Type: Article

References (20)

1. Clarke, N. W., McClure, J. and George, N. J.: Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol, 68: 74, 1991
2. Daniell, H. W., Dunn, S. R., Ferguson, D. W., Lomas, G., Niazi, Z. and Stratte, P. T.: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol, 163: 181, 2000
3. Berruti, A., Dogliotti, L., Bitossi, R., Fasolis, G., Gorzegno, G., Bellina, M. et al: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol, 164: 1248, 2000
4. Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A. et al: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med, 345: 948, 2001
5. Lipton, A., Theriault, R. L., Hortobagyi, G. N., Simeone, J., Knight, R. D., Mellars, K. et al: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer, 88: 1082, 2000
6. Diel, I. J., Solomayer, E. F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D. et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med, 339: 357, 1998
7. Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, G. D. et al: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res, 10: 1478, 1995
8. Lee, M. V., Fong, E. M., Singer, F. R. and Guenette, R. S.: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res, 61: 2602, 2001
9. Benford, H. L., Frith, J. C., Auriola, S., Monkkonen, J. and Rogers, M. J.: Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol, 56: 131, 1999
10. Cory, A. H., Owen, T. C., Barltrop, J. A. and Cory, J. G.: Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun, 3: 207, 1991
11. Mumby, S. M., Heukeroth, R. O., Gordon, J. I. and Gilman, A. G.: G-protein alpha-subunit expression, myristoylation, and membrane association in COS cells. Proc Natl Acad Sci USA, 87: 728, 1990
12. Crick, D. C., Andres, D. A. and Waechter, C. J.: Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem Biophys Res Commun, 237: 483, 1997
13. Boissier, S., Ferreras, M., Peyruchaud, O., Magnetto, S., Ebetino, F. H., Colombel, M. et al: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res, 60: 2949, 2000
14. Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D. et al: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest, 88: 2095, 1991
15. Luckman, S. P., Hughes, D. E., Coxon, F. P., Graham, R., Russell, G. and Rogers, M. J.: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res, 13: 581, 1998
16. van Beek, E., Pieterman, E., Cohen, L., Lowik, C. and Papapoulos, S.: Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun, 264: 108, 1999
17. Fisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J. et al: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA, 96: 133, 1999
18. van Beek, E., Hoekstra, M., van de Ruit, M., Lowik, C. and Papapoulos, S.: Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res, 9: 1875, 1994
19. Konishi, N., Hiasa, Y., Tsuzuki, T., Tao, M., Enomoto, T. and Miller, G. J.: Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate, 30: 53, 1997
20. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, J. B., Oliff, A. et al: A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res, 55: 5302, 1995